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Background: Human umbilical cord blood cells (HUCBCs) were used to investigate 
the mechanisms underlying the beneficial effects of cord blood cells in spinal cord 
injury (SCI).
Methods: Rats were divided into three groups: (1) sham operation (laminectomy 
only); (2) laminectomy + SCI + human adult peripheral blood mononucleocytes (PBMCs) 
(5 × 106/0.3 mL); and (3) laminectomy + SCI + HUCBCs (5 × 106/0.3 mL). SCI was induced 
by compressing the spinal cord for 1 minute with an aneurysm clip calibrated to 
55 g closing pressure. HUCBCs were infused immediately after SCI via the tail vein. 
Behavioral function tests measuring the maximal angle at which an animal could hold 
onto the inclined plane were conducted on days 1, 4 and 7 after SCI. Serum levels 
of tumor necrosis factor (TNF)-α and interleukin (IL)-10, were assayed. Further more, 
to determine if glial cell line-derived neurotrophic factor (GDNF) or vascular 
endothelial growth factor (VEGF) could be detected in the spinal cord injured area 
after systemic HUCBC infusion, analysis of these two molecules was conducted by 
immunofluorescence.
Results: Systemic HUCBC infusion significantly attenuated SCI-induced hind limb 
dysfunction. The serum IL-10 levels were increased, but TNF-α levels were decreased 
after HUCBC infusion. Both VEGF and GDNF could be detected in the injured spinal 
cord after transplantation of HUCBC, but not PBMC, cells.
Conclusion: Our results demonstrate that HUCBC therapy may be beneficial for the 
recovery of SCI-induced hind limb dysfunction by increasing serum levels of IL-10, 
VEGF and GDNF in SCI rats.
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1. Introduction
Although enormous progress has been made in the 
field of cell transplantation in the last two decades, 
American governmental restrictions on embryonic 
stem cells, negative outcomes reported from clinical 
trials, and ethical concerns over the use of cells from 
fetal or embryonic sources have slowed progress in 
cell replacement and repair. However, we believe 
the most promising cells are those of hematopoietic 
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origin, specifically human umbilical cord blood cells 
(HUCBCs). These cells have been used extensively 
over the last 20 years to treat various nonmalignant 
and malignant hematopoietic diseases, particularly 
in children.1,2
HUCBCs are also strong candidates for use in cell 
therapy for spinal cord injury (SCI) because of their 
availability, weak immunogenicity, and low risk of 
mediating viral transmission.3 For example, intra-
spinal transplantation of CD34+ cells derived from 
HUCBCs after spinal cord hemisection4 or contusion5 
injury improved hind limb functional recovery in 
adult rats, and Saporta et al6 also reported that 
intravenous (IV) infusion of unfractionated HUCBCs 
improved hind limb function in a rat model of spinal 
cord compression.
Trauma to the central nervous system triggers 
intraparenchymal inflammation and activation of 
systemic immunity, with the capacity to exacer-
bate neuropathology and stimulate mechanisms of 
tissue repair.7 Despite our incomplete understand-
ing of the mechanisms that control these divergent 
functions, immune-based therapies are becoming a 
therapeutic focus. Furthermore, cord blood lympho-
cytes express cytokine receptors (interleukin [IL]-2, 
IL-4, IL-6, IL-7, tumor necrosis factor [TNF]-α, and 
interferon-γ) at lower levels than adult blood cells8 
and produce large amounts of the anti-inflammatory 
cytokine, IL-10.9 However, it remains to be deter-
mined what factors or mediators secreted from 
HUCBCs are crucial for restoration of the injured 
spinal cord in the acute stage of SCI.
2. Methods
2.1. Animals
Adult male Sprague-Dawley rats (weight, 278 ± 14 g) 
were obtained from the Animal Resource Center 
of the National Science Council of the Republic of 
China (Taipei, Taiwan). The animals were housed, 
four in a group, at an ambient temperature of 
22 ± 1°C, with a 12-hour light−dark cycle. Pellet rat 
chow and tap water were available ad libitum. All 
protocols were approved by the Animal Ethics 
Committee of the Chi Mei Medical Center (Tainan, 
Taiwan) in accordance with the Guidelines for the 
Care and Use of Laboratory Animals of the National 
Institutes of Health and the Guidelines of the 
Animal Welfare Act.
2.2. Surgery
Laminectomy, with removal of the vertebral 
peduncle, was performed at T8/T9 on rats anes-
thetized with sodium pentobarbital (25 mg/kg, 
intraperitoneal; Sigma Chemical Co., St. Louis, MO, 
USA) and a mixture containing ketamine (44 mg/kg, 
intramuscular; Nankuang Pharmaceutical, Taiwan), 
atropine (0.02633 mg/kg, intramuscular; Sintong 
Chemical Industrial Co., Taiwan), and xylazine 
(6.77 mg/kg, intramuscular; Bayer, Germany). The 
jaws of a calibrated aneurysm clip with a closing 
pressure of 55 g were placed between the dorsal 
and ventral surfaces of the spinal cord and left 
in place for 1 minute.10 Sham-operated control 
animals received the same laminectomy, but the 
spinal cord was not compressed. All animals were 
given 0.1 mL of fluoroquinolone (Baytril, Bayer, 
Germany) antibiotic for 3 days following surgery. 
Animals with SCI were individually housed on spe-
cial bedding to prevent skin breakdown, and had 
their bowels and bladders manually expressed twice 
daily. Food and water were freely accessible at a 
lowered height in their cages.
2.3. Preparation of PBMCs and HUCBCs
With approval for this project from the Institu-
tional Review Board of Chi Mei Medical Center 
(Tainan, Taiwan), human peripheral blood mono-
nucleocytes (PBMCs) and HUCBCs were obtained 
from freshly collected buffy coat fractions from 
healthy donors at Chi Mei Medical Center. HUCBCs 
were isolated by centrifugation over a Ficoll-Paque 
(Farmacia, Uppsala, Sweden) density gradient at 
400 g for 30 minutes at room temperature in a 
Sorvall 6000B (Du Pont, DE, USA). The cells col-
lected at the interface were washed three times 
with serum-free Roswell Park Memorial Institute 
(RPMI)-1640 (Gibco-BRL, Grand Island, NY, USA) 
and subsequently resuspended in serum-free lym-
phocyte medium (Gibco-BRL) and stored at 37°C in 
an incubator. The PBMCs at a concentration of 
5 × 106 cells in 0.3 mL were prepared and stored at 
37°C in an incubator. For IV administration, a 26-
gauge needle was inserted into the tail vein, and 
cells (0.3 mL) were delivered over a 1-minute period.
2.4. Experimental groups
Animals were assigned randomly to one of the fol-
lowing three major groups: (1) one group of rats 
was treated with laminectomy at T8/T9, followed 
immediately by IV infusion of PBMCs (5 × 106 in 
0.3 mL) per rat; (2) the second group of animals 
was treated with laminectomy at T8/T9, followed 
immediately by an IV infusion of HUCBCs (5 × 106 
in 0.3 mL); and (3) the third group of animals was 
used as a sham-operated control group.
In experiment 1, an IV dose of HUCBCs, PBMCs 
(5 × 106 in 0.3 mL) or saline was randomly adminis-
tered immediately after SCI (n = 12), and their effects 
on the maximal angle that animals could cling to on 
an inclined plane were assessed 1−7 days after SCI.
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In experiment 2, an IV dose of HUCBCs, PBMCs 
(5 × 106 in 0.3 mL) or saline was randomly adminis-
tered immediately after SCI (n = 12), and their ef-
fects on the serum levels of IL-10 and TNF-α were 
assessed 1−7 days after SCI.
In experiment 3, an IV dose of HUCBCs (5 × 106 in 
0.3 mL) or PBMCs (5 × 106 in 0.3 mL) was randomly 
administered immediately after SCI, and their ef-
fects on the amounts of vascular endothelial growth 
factor (VEGF)- and glial cell line-derived neuro-
trophic factor (GDNF)-positive cells in the injured 
spinal cord were assessed 7 days after SCI (n = 12).
2.5. Inclined plane
The inclined plane was used to measure limb 
strength. Animals were placed, facing right and 
then left, perpendicular to the slope of a 20 × 20 cm 
ribbed surface on an inclined plane, starting at an 
angle of 55°.11 The angle was increased or decreased 
in 5° increments to determine the maximal angle 
at which an animal could hold to the plane. Data for 
each day were the mean of the left- and right-side 
maximal angles. All behavioral tests were indepen-
dently scored by two observers who were unaware 
of prior treatment. These scores were averaged to 
arrive at a mean score for each animal for the 
behavioral session.
2.6. Assay of cytokines
For determination of TNF-α and IL-10, blood sam-
ples were taken 3 days after SCI, or the equivalent 
time for the sham-operated rats. The blood samples 
were allowed to clot for 2 hours at room tempera-
ture and then centrifuged (2000 g, 20 minutes, 4°C). 
The supernatants were collected and stored at −70°C 
until time of measurement. The concentrations of 
TNF-α and IL-10 in serum were de termined using 
double-antibody sandwich enzyme-linked immuno-
sorbent assay (ELISA; R&D Systems, Minneapolis, 
MN, USA) according to the manufacturer’s instruc-
tions. Optical densities were read on a plate reader 
set at 450 nm for TNF-α and IL-10. The concentra-
tions of TNF-α and IL-10 in the samples were cal-
culated from the standard curve multiplied by the 
dilution factor, and were expressed as pg/mL.
2.7. Immunohistochemistry
Autofluorescence was quenched using the method 
of Vendrame et al,12 after which the spinal cord 
sections were incubated with mouse monoclonal 
antibody against human nuclei (HuNu; Chemicon 
Inc., Pittsburgh, PA, USA), followed by fluorescein 
isothiocyanate-conjugated goat anti-mouse sec-
ondary antibody (Annexin Alexa; Molecular Probes, 
Eugene, OR, USA). 4,6-Diamidino-2-phenylindole 
(DAPI) staining (Molecular Probes, Eugene, OR, USA) 
was performed to visualize nucleated cells. Slides 
were examined under epifluorescence on an Olympus 
BX60 microscope. For determination of VEGF and 
GDNF expression at the level of T8 to T9 sections, the 
sections were incubated with phosphate-buffered 
saline containing anti-VEGF and anti-GDNF mouse 
antibody at 1:200 dilution and then detected with 
Alexa-Fluor 568 (Molecular Probes, Eugene, OR, USA) 
goat antimouse (IgG) antibody.
2.8. Statistical analysis
Data are presented as the mean ± standard error of 
the mean. Repeated measures analysis of variance 
was conducted to test the treatment-by-time inter-
actions and the effect of treatment over time on each 
score. The Duncan’s multiple-range test was used for 
post hoc multiple comparisons among means. A p < 
0.05 was considered to be statistically significant.
3. Results
3.1.  HUCBCs improved motor performance 
after SCI
Behavioral tests of motor function were conducted 
on days 1, 4 and 7 after SCI to determine whether 
HUCBC therapy, applied immediately after SCI, 
could produce immediate and significant effects. 
As shown in Figure 1, although PBMC therapy was 
ineffective in all tests at these time points, the 
SCI-induced motor deficits, measured by the maxi-
mal angle at which an animal could hold to the in-
clined plane, were completely abrogated at days 
4−7 after SCI by an IV dose of HUCBCs administered 
immediately after SCI (Figure 1).
3.2.  HUCBCs decreased TNF-a but 
stimulated IL-10 production in 
serum after SCI
The serum levels of both TNF-α and IL-10 were 
measured on day 3 after SCI. ELISA revealed that 
HUCBC therapy significantly attenuated the over-
production of TNF-α (Figure 2) by 3 days after SCI. 
However, the serum levels of IL-10 were signifi-
cantly elevated by HUCBC therapy, at 3 days after 
SCI (Figure 2).
3.3.  HUCBCs increased both endogenous 
VEGF and GDNF
To demonstrate if GDNF or VEGF could be secreted 
by the HUCBCs in the spinal cord-injured area, 
sections of injured spinal cord were analyzed for 
VEGF and GDNF using immunofluorescence. This 
80 C.T. Chen et al
staining revealed that, after 7 days, the spinal cord-
injured rats treated with HUCBC infusion, but not 
PBMC therapy, displayed an increased number of 
VEGF- (∼60) and GDNF-positive cells (∼90) in their 
injured spinal cord sections (Figures 3 and 4), com-
pared with those of PBMC-treated groups.
3.4.  Delivered HUCBCs were localized to 
spinal cord injured area as determined 
by immunohistochemistry
Human nuclei immunoreactive cells were detected 
in the spinal cord-injured area of animals injected 
with 5 × 106 HUCBCs, but not with PBMCs, immedi-
ately after SCI, by DAPI staining (Figure 5). This re-
vealed that HUCBCs could be detected in the spinal 
cord-injured section 7 days after transplantation.
4. Discussion
In this study, systemic infusion of HUCBCs improved 
functional recovery in rats with spinal cord inju-
ries. HUCBCs are rich in hematopoietic stem cells 
(CD34+ cells).13 Two percent of the HUCBCs are stem 
cells capable of reconstituting blood lineages. These 
HUCBCs have been used to reconstitute bone mar-
row and blood cell lineages in children with malig-
nant and nonmalignant diseases.14 In the present 
study, HUCBCs were transplanted via the tail vein 
immediately after SCI, and CD34+ cells transplanted 
directly into the spinal cord 1 week after injury 
have also been shown to improve functional recov-
ery in rats.5 These investigators reported that trans-
planted CD34+ cells survived in the host spinal cord 
for at least 3 weeks after transplantation, but had 
disappeared by 5 weeks.5 In addition, it was found 
that IV infusion of HUCBCs alone showed therapeu-
tic effects when administered 24 hours to 7 days 
after stroke15,16 or traumatic brain injury.17 The 
results reported here are consistent with several 
previous findings.4,5 In our present study, the rats 
were receiving no immunosuppression, which is 
generally a requisite for long-term graft survival but 
is often accompanied by deleterious side effects. 
However, transplantation was still able to provide 
neuroprotection, even under these conditions.
Davies et al18 reported that elevated serum levels 
of circulating proinflammatory cytokines (e.g., IL-1β, 
IL-6 and TNF-α) and autoantibodies were present 
in SCI subjects without medical complications. 
Hence, degradation of serum proinflammatory cy-
tokines might be crucial for functional recovery 
after SCI in the acute stage. Our previous results 
showed that CD34+ cells exerted anti-inflammatory 
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Figure 1 Maximal angle indicated animals could cling 
to on an inclined plane. *Maximum grip angle 1−7 days 
following spinal cord injury (SCI) was significantly de-
creased (p < 0.05) for SCI animals treated with intrave-
nous peripheral blood mononucleocytes (PBMCs; 5 × 106/
0.3 mL) () compared with sham controls (); †maxi-
mum grip angle 4−7 days following SCI was significantly 
increased (p < 0.05) for SCI animals treated with intrave-
nous human umbilical cord blood cells (HUCBCs; 5 × 106/
0.3 mL) () compared with PBMC-treated SCI animals 
(ANOVA followed by Duncan’s test; n = 12 per group). 
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Figure 2 Serum levels of both interleukin (IL)-10 and 
tumor necrosis factor (TNF)-α. *The serum levels of TNF-α 
of rats 3 days following spinal cord injury (SCI) were sig-
nificantly increased (p < 0.05; n = 12) for SCI animals 
treated with peripheral blood mononucleocytes (PBMCs; 
5 × 106/0.3 mL) () compared with sham-operated con-
trols; †the serum levels of IL-10 or TNF-α of rats 3 days 
following SCI were significantly increased or decreased 
(p < 0.05; n = 12), respectively, for SCI animals treated 
with human umbilical cord blood cells (HUCBCs; 
5 × 106/0.3 mL) () compared with PBMC-treated group. 
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effects in animal models of heatstroke.19 The pres-
ent findings further demonstrated that HUCBC ther-
apy caused a significant increase in the serum levels 
of IL-10, accompanied by a reduction in TNF-α 
overproduction during SCI. In fact, IL-10 possesses 
important anti-inflammatory properties through sup-
pression of TNF-α and other pro-inflammatory cyto-
kines.20 Our data imply that HUCBCs may improve 
hind limb function after SCI by increasing IL-10 and 
decreasing TNF-α production.
VE
G
F-
po
si
ti
ve
 c
el
ls
0
20
40
60
80
*
Sham SCI + PBMC SCI + HUCBC
Figure 3 Vascular endothelial growth factor (VEGF)-positive cells. *The numbers of VEGF-positive cells in injured 
spinal cord section of rats 3 days following spinal cord injury (SCI) were significantly increased (p < 0.05; n = 12) for SCI 
animals treated with human umbilical cord blood cells (HUCBCs; 5 × 106/0.3 mL) () compared with peripheral blood 
mononucleocytes (PBMC)-treated groups. Representative sample of VEGF-positive cell stained spinal cord sections 
from animals sacrificed at 72 hours post-SCI are depicted in the upper panel.
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Figure 4 Glial cell line-derived neurotrophic factor (GDNF)-positive cells. *The numbers of GDNF-positive cells in 
injured spinal cord of rats 3 days following spinal cord injury (SCI) were significantly increased (p < 0.05; n = 12) for SCI 
animals treated with human umbilical cord blood cells (HUCBCs; 5 × 106/0.3 mL) () compared with peripheral blood 
mononucleocytes (PBMCs; 5 × 106/0.3 mL). Representative sample of GDNF-positive cell stained spinal cord sections 
from animals sacrificed at 72 hours post-SCI are depicted in the upper panel.
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Therapeutic vascular growth is a new concept 
in the treatment of ischemic vascular diseases. The 
members of the VEGF family regulate all types of 
vascular growth.21 Various strategies have been pres-
ented for the use of post-ischemia vasculogenesis. 
Indeed, as shown by the present results, systemic 
administration of HUCBCs stimulated production 
of both VEGF and GDNF in the injured spinal cord. 
These findings support the hypothesis that HUCBCs 
may promote an environment conducive to revascu-
larization of ischemic spinal cord, so that neuronal 
regeneration can proceed. This hypothesis is sup-
ported by several studies. A rich vascular environ-
ment, along with generation of VEGF may enhance 
subsequent neuronal regeneration.22,23 Summarizing 
these observations, it appears that HUCBCs may im-
prove functional recovery after SCI by enhancing 
neovessel formation and accelerating endogenous 
neurogenesis.
Some researchers have reported that HUCBC 
grafts, instead of the host tissues per se, were likely 
to be the source of neuroprotective trophic factors.24 
The expression of several neurotrophic factors in 
the brain are influenced by cerebral ischemia.25,26 
GDNF is a well-known neurotrophic factor that 
promotes the survival and morphologic differentia-
tion of dopaminergic neurons and motoneurons.27,28 
Topical application of GDNF and adenovirus-medi-
ated GDNF gene transfer significantly attenuated 
infarct size in a rat middle cerebral artery occlu-
sion model,29,30 while mesenchymal stem cells that 
produced GDNF also lessened ischemic damage in 
the rat middle cerebral artery occlusion model.31 
In our previous studies, we demonstrated that sys-
temic exogenous administration of GDNF improved 
functional recovery in SCI rats.32 In the present study, 
systemic infusion of HUCBCs, but not PBMCs, signi-
ficantly increased the production of GDNF in the 
injured spinal cord 4−7 days after injury. Thus, it is 
likely that HUCBCs may restore hind limb motor 
function in the rat SCI model by producing GDNF 
and/or other neurotrophic factors.
Although this study used xenografted cells, the 
HUCBCs did not cause critical morbidity after trans-
plantation. This may have been because of weak im-
munogenicity and the short observation period of 
the study, as we focused on treatment of the acute 
stage. Further studies should aim to examine the ef-
fects of HUCBCs during chronic SCI and to compare 
the differences between acute and chronic SCI.
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Figure 5 Human umbilical cord blood cell (HUCBC) identification by human nuclei antibody immunoreactivity in the 
spinal cord of a spinal cord injured rat that re ceived HUCBCs (5 × 106/0.3 mL) (SCI + HUCBC), peripheral blood mono-
nucleocytes (PBMCs; 5 × 106/0.3 mL) (SCI + PBMC) and a sham control. DAPI = 4,6-diamidino-2-phenylindole; FITC = flu-
orescein isothiocyanate.
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In summary, the current findings demonstrate 
that systemic administration of HUCBCs promotes 
the recovery of hind limb function in an SCI model, 
through stimulating the production of IL-10, GDNF 
and VEGF. Collection of HUCBCs by pediatricians 
or obstetricians in the delivery room is relatively 
straightforward; the procedures are easy and pose 
no risk to mother or baby. In addition, HUCBCs are 
safe to use and associated with few ethical issues, 
as compared with bone marrow transplantation. 
Thus, it appears that HUCBC therapy is a potentially 
useful strategy for the treatment of SCI.
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